# Cochrane

# Trusted evidence.

# Informed decisions.

# Better health.

# Analysis 1.10. Comparison 1: Fecal microbiota transplantation (FMT) versus control for induction of remission in ulcerative colitis (UC), Outcome 10: Induction of clinical remission in UC at longest follow-up: composite of clinical score and endoscopic score

|Study or Subgroup|FMT Events|FMT Total|Control Events|Control Total|Weight|Risk Ratio M-H, Random, 95% CI|Risk Ratio M-H, Random, 95% CI|
|---|---|---|---|---|---|---|---|
|Březina 2021|12|23|8|22|26.3%|1.43 [0.73 , 2.82]| |
|Costello 2019|12|38|3|35|8.7%|3.68 [1.13 , 11.98]| |
|Crothers 2021|2|7|0|8|1.5%|5.63 [0.31 , 100.52]| |
|Fang 2021|9|10|5|10|28.3%|1.80 [0.94 , 3.46]| |
|Haifer 2022|8|15|3|20|9.2%|3.56 [1.13 , 11.18]| |
|Moayyedi 2015|9|38|2|37|5.6%|4.38 [1.01 , 18.94]| |
|Paramsothy 2017|11|41|3|40|8.4%|3.58 [1.08 , 11.88]| |
|Rossen 2015|7|23|5|25|12.1%|1.52 [0.56 , 4.13]| |
|Total (95% CI)|70|195|29|197|100.0%|2.13 [1.51 , 3.02]| |

Total events: 70 / 29

Heterogeneity: Tau² = 0.00; Chi² = 6.24, df = 7 (P = 0.51); I² = 0%

Test for overall effect: Z = 4.27 (P < 0.0001)

Test for subgroup differences: Not applicable

# Analysis 1.11. Comparison 1: Fecal microbiota transplantation (FMT) versus control for induction of remission in ulcerative colitis (UC), Outcome 11: Serious adverse events for induction of remission in UC

|Study or Subgroup|FMT Events|FMT Total|Control Events|Control Total|Weight|Risk Ratio M-H, Random, 95% CI|Risk Ratio M-H, Random, 95% CI|Risk of Bias|
|---|---|---|---|---|---|---|---|---|
|Březina 2021|4|23|1|22|10.9%|3.83 [0.46 , 31.62]| |+ ? − + + + +|
|Costello 2019|3|38|2|35|16.3%|1.38 [0.25 , 7.79]| |+ + + + + +|
|Crothers 2021|1|7|1|8|7.3%|1.14 [0.09 , 15.08]| |+ + + + − +|
|Fang 2021|0|10|0|10| |Not estimable| |+ ? − + + +|
|Haifer 2022|2|15|2|20|14.4%|1.33 [0.21 , 8.41]| |+ + + + + +|
|Moayyedi 2015 (1)|3|38|2|37|16.3%|1.46 [0.26 , 8.25]| |+ + + + + +|
|Pai 2021|5|13|1|12|12.2%|4.62 [0.63 , 34.05]| |+ + + − − +|
|Paramsothy 2017|2|41|1|40|8.7%|1.95 [0.18 , 20.68]| |+ + + + + +|
|Rossen 2015|2|23|2|25|13.8%|1.09 [0.17 , 7.10]| |+ + + + + +|
|Sarbagili Shabat 2022|0|36|0|15| |Not estimable| |+ + + + + +|
|Total (95% CI)|22|244|12|224|100.0%|1.77 [0.88 , 3.55]| | |

Total events: 22 / 12

Heterogeneity: Tau² = 0.00; Chi² = 2.01, df = 7 (P = 0.96); I² = 0%

Test for overall effect: Z = 1.60 (P = 0.11)

Test for subgroup differences: Not applicable

# Footnotes

(1) FMT, 2 diagnoses changed to Crohn's colitis and 1 positive for C difficile toxin at end of therapy; control, 1 diagnosis changed to Crohn's colitis and 1 hospitalised.

# Risk of bias legend

(A) Random sequence generation (selection bias)

(B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

# Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.